JP2004502789A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004502789A5 JP2004502789A5 JP2002511783A JP2002511783A JP2004502789A5 JP 2004502789 A5 JP2004502789 A5 JP 2004502789A5 JP 2002511783 A JP2002511783 A JP 2002511783A JP 2002511783 A JP2002511783 A JP 2002511783A JP 2004502789 A5 JP2004502789 A5 JP 2004502789A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- kit
- chemotherapeutic agent
- hyaluronan
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940099552 hyaluronan Drugs 0.000 description 25
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 25
- 229920002674 hyaluronan Polymers 0.000 description 25
- 239000002246 antineoplastic agent Substances 0.000 description 20
- 229940127089 cytotoxic agent Drugs 0.000 description 19
- 230000000699 topical effect Effects 0.000 description 9
- 229960002949 fluorouracil Drugs 0.000 description 6
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical group ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229960004768 irinotecan Drugs 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 229940063725 leukeran Drugs 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 229940063179 platinol Drugs 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPQ8795A AUPQ879500A0 (en) | 2000-07-14 | 2000-07-14 | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease |
| AUPQ8795 | 2000-07-14 | ||
| PCT/AU2001/000849 WO2002005852A1 (en) | 2000-07-14 | 2001-07-13 | Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012123354A Division JP2012162569A (ja) | 2000-07-14 | 2012-05-30 | 疾患の処置における細胞毒性物質、薬物プレ増感剤および化学増感剤としてのヒアルロナン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004502789A JP2004502789A (ja) | 2004-01-29 |
| JP2004502789A5 true JP2004502789A5 (enExample) | 2008-08-28 |
| JP5548328B2 JP5548328B2 (ja) | 2014-07-16 |
Family
ID=3822859
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002511783A Expired - Fee Related JP5548328B2 (ja) | 2000-07-14 | 2001-07-13 | 疾患の処置における細胞毒性物質、薬物プレ増感剤および化学増感剤としてのヒアルロナン |
| JP2012123354A Pending JP2012162569A (ja) | 2000-07-14 | 2012-05-30 | 疾患の処置における細胞毒性物質、薬物プレ増感剤および化学増感剤としてのヒアルロナン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012123354A Pending JP2012162569A (ja) | 2000-07-14 | 2012-05-30 | 疾患の処置における細胞毒性物質、薬物プレ増感剤および化学増感剤としてのヒアルロナン |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20030180382A1 (enExample) |
| EP (1) | EP1301209A4 (enExample) |
| JP (2) | JP5548328B2 (enExample) |
| CN (1) | CN1388760A (enExample) |
| AU (1) | AUPQ879500A0 (enExample) |
| CA (1) | CA2382560C (enExample) |
| GB (1) | GB2368525B (enExample) |
| NZ (1) | NZ517359A (enExample) |
| WO (1) | WO2002005852A1 (enExample) |
| ZA (1) | ZA200201561B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1041209A1 (zh) | 1999-01-13 | 2002-07-05 | Meditech Research Limited | 加強藥物療效的成份及方法 |
| AUPQ879500A0 (en) * | 2000-07-14 | 2000-08-10 | Meditech Research Limited | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease |
| US9066919B2 (en) * | 2000-07-14 | 2015-06-30 | Alchemia Oncology Pty Limited | Hyaluronan as a chemo-sensitizer in the treatment of cancer |
| CA2458856C (en) * | 2001-08-27 | 2011-02-15 | Meditech Research Limited | Improved therapeutic protocols |
| WO2004003545A1 (en) | 2002-07-01 | 2004-01-08 | Tufts University | Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers |
| CA2616607C (en) * | 2005-07-27 | 2015-06-02 | Alchemia Oncology Pty Limited | Therapeutic protocols using hyaluronan |
| EA013877B1 (ru) * | 2005-09-07 | 2010-08-30 | Алкемиа Онколоджи Пти Лимитед | Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения |
| JP2007153766A (ja) * | 2005-12-01 | 2007-06-21 | Toshitsu Kagaku Kenkyusho:Kk | Ｍａｐキナーゼキナーゼキナーゼ遺伝子の発現増強剤 |
| WO2008041514A1 (ja) | 2006-09-22 | 2008-04-10 | Kochi University | 放射線または抗がん化学療法増感剤 |
| KR101224711B1 (ko) * | 2008-01-30 | 2013-01-21 | 유니버시티 오브 캔사스 | 림프관내 화학요법 약물 담체 |
| JP6091431B2 (ja) * | 2011-01-31 | 2017-03-15 | ルコラス−エム．ディー．リミテッド | 医薬的使用 |
| US9316645B2 (en) | 2011-10-07 | 2016-04-19 | Brown University | Methods, compositions and kits for imaging cells and tissues using nanoparticles and spatial frequency heterodyne imaging |
| US20130236504A1 (en) * | 2012-03-06 | 2013-09-12 | Medical University Of South Carolina | Delivery System for Enhancing Drug Efficacy |
| WO2014015264A1 (en) | 2012-07-20 | 2014-01-23 | Brown University | Functionalized media and methods of making and using therefor |
| EP2712651A1 (en) | 2012-09-27 | 2014-04-02 | F. Hoffmann-La Roche AG | Venting device for use in ambulatory infusion system |
| EP2712650A1 (en) | 2012-09-27 | 2014-04-02 | F. Hoffmann-La Roche AG | Adapter and drug cartridge alignment device |
| TR201905159T4 (tr) | 2013-02-15 | 2019-05-21 | Kortuc Inc | İntratümöral lokal enjeksiyonda ve taşıyıcı olarak hidrojel ile hidrojen peroksidin kontrollü salımı için kullanılacak radyasyon/kemoterapi sensitizörü. |
| CN109528763A (zh) * | 2018-12-29 | 2019-03-29 | 江苏靶标生物医药研究所有限公司 | 顺铂与透明质酸钠的组合物 |
| CN109512825A (zh) * | 2018-12-29 | 2019-03-26 | 江苏靶标生物医药研究所有限公司 | 一种铂类化合物和透明质酸钠的组合物及其应用 |
| WO2022173895A1 (en) * | 2021-02-11 | 2022-08-18 | Virginia Commonwealth University | Methods for preventing cancer relapse |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA612307A (en) | 1961-01-10 | International Business Machines Corporation | Hydraulic drive tape handling system | |
| US4141973A (en) * | 1975-10-17 | 1979-02-27 | Biotrics, Inc. | Ultrapure hyaluronic acid and the use thereof |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5166331A (en) | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| IT1229075B (it) | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico |
| FR2553099B1 (fr) | 1983-10-11 | 1989-09-08 | Fidia Spa | Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant |
| JPS6117A (ja) * | 1984-06-11 | 1986-01-06 | Seikagaku Kogyo Co Ltd | ムコ多糖系癌転移抑制剤 |
| CA1227427A (en) | 1984-08-16 | 1987-09-29 | Albert Landsberger | Therapeutic agent for the use in cancer treatment |
| JPS6191986U (enExample) | 1984-11-24 | 1986-06-14 | ||
| US5532341A (en) | 1985-03-28 | 1996-07-02 | Sloan-Kettering Institute For Cancer Research | Human pluripotent hematopoietic colony stimulating factor |
| US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
| US5202431A (en) | 1985-07-08 | 1993-04-13 | Fidia, S.P.A. | Partial esters of hyaluronic acid |
| US4665107A (en) | 1986-03-21 | 1987-05-12 | Koh-I-Noor Rapidograph, Inc. | Pigment encapsulated latex aqueous colorant dispersions |
| IT1198449B (it) | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | Esteri di alcoli polivalenti di acido ialuronico |
| IT1219587B (it) | 1988-05-13 | 1990-05-18 | Fidia Farmaceutici | Polisaccaridi carbossiilici autoreticolati |
| US5128450A (en) | 1989-06-30 | 1992-07-07 | Urdal David L | Nonglycosylated human interleukin-3 analog proteins |
| CA1340994C (en) | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5095037B1 (en) | 1989-12-21 | 1995-12-19 | Nissho Kk | Combined anti-inflammatory agent |
| CA2061703C (en) * | 1992-02-20 | 2002-07-02 | Rudolf E. Falk | Formulations containing hyaluronic acid |
| CA2061566C (en) | 1992-02-20 | 2002-07-09 | Rudolf E. Falk | Treatment of disease employing hyaluronic acid and nsaids |
| US5733891A (en) * | 1990-10-18 | 1998-03-31 | Shiseido Co., Ltd. | Compound for medicinal ingredient and hyaluronic acid and process for producing the same |
| US5416071A (en) | 1991-03-12 | 1995-05-16 | Takeda Chemical Industries, Ltd. | Water-soluble composition for sustained-release containing epo and hyaluronic acid |
| JP3507486B2 (ja) | 1991-03-15 | 2004-03-15 | アムジエン・インコーポレーテツド | 顆粒球コロニー刺激因子の肺内投与 |
| US5977088A (en) * | 1991-07-03 | 1999-11-02 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
| US6475795B1 (en) | 1991-07-03 | 2002-11-05 | Meditech Research, Ltd. | Use of hyaluronan in gene therapy |
| CA2122519C (en) * | 1994-04-29 | 2001-02-20 | Rudolf Edgar Dr. Falk | Cancer treatment and metastasis prevention |
| EP0563475B1 (en) | 1992-03-25 | 2000-05-31 | Immunogen Inc | Cell binding agent conjugates of derivatives of CC-1065 |
| US5287123A (en) * | 1992-05-01 | 1994-02-15 | Hewlett-Packard Company | Preheat roller for thermal ink-jet printer |
| EP0680337A4 (en) | 1993-01-12 | 1997-07-30 | Anthony George Gristina | METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY. |
| CA2089621A1 (en) * | 1993-02-16 | 1994-08-17 | Rudolf Edgar Falk | Formulations containing hyaluronic acid |
| US5847002A (en) | 1993-04-16 | 1998-12-08 | Hyal Pharmaceutical Corporation | Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID |
| CA2094203A1 (en) | 1993-04-16 | 1994-10-17 | Derek A. Willoughby | Inhibition of angiogenesis |
| US5744155A (en) | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
| ITPD940054A1 (it) | 1994-03-23 | 1995-09-23 | Fidia Advanced Biopolymers Srl | Polisaccaridi solfatati |
| AU2479695A (en) | 1994-05-09 | 1995-11-29 | Hadasit Medical Research Services & Development Company Ltd | Prevention of tumor metastasis |
| AU3159595A (en) | 1994-08-30 | 1996-03-22 | Hyal Pharmaceutical Corporation | Hyaluronic acid and derivatives for modulation of cellular activity |
| WO1997009998A2 (en) | 1995-09-14 | 1997-03-20 | Bristol-Myers Squibb Company | Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors |
| WO1997010841A1 (en) * | 1995-09-18 | 1997-03-27 | The Trustees Of Columbia University In The City Of New York | Antiangiogenic properties of endothelial-monocyte activating polypeptide ii |
| US5968972A (en) | 1995-10-26 | 1999-10-19 | Baker Norton Pharmaceuticals, Inc. | Method for increasing the oral bioactivity of pharmaceutical agents |
| JP2000513707A (ja) | 1995-12-01 | 2000-10-17 | ハイアル ファーマスティカル コーポレイション | 投与薬剤の目標化、治療薬および他のグリコサミノグリカン（ｇａｇｓ） |
| US5776925A (en) * | 1996-01-25 | 1998-07-07 | Pharmacyclics, Inc. | Methods for cancer chemosensitization |
| DE69700887T2 (de) | 1996-01-31 | 2000-06-29 | Nisshin Flour Milling Co., Ltd. | Isoprenderivate |
| AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
| KR100236771B1 (ko) | 1997-04-01 | 2000-02-01 | 성재갑 | 히아루론산을 이용한 약물의 서방성 미세입자 제형 |
| CA2175282A1 (en) * | 1996-04-29 | 1997-10-30 | Rudolf Edgar Falk | Use of forms of hyaluronic acid (ha) for the treatment of cancer |
| US5756537A (en) | 1996-11-08 | 1998-05-26 | Parkash S. Gill, M.D., Inc. | Regime for paclitaxel in Kaposi's sarcoma patients |
| IT1286510B1 (it) | 1996-11-29 | 1998-07-15 | Cooperativa Centro Ricerche Po | Esteri butirrici ad attivita' antiproliferativa e composizioni farmaceutiche che li contengono |
| US6232301B1 (en) * | 1996-12-27 | 2001-05-15 | Seikagaku Corporation | Remedies for bladder disorders |
| DK0971961T3 (da) | 1997-04-04 | 2003-03-24 | Fidia Advanced Biopolymers Srl | N-sulfaterede hyaluronsyreforbindelser, derivater deraf og en fremgangsmåde til deres fremstilling |
| CA2208924A1 (en) | 1997-07-09 | 1999-01-09 | Hyal Pharmaceutical Corporation | Sparing paclitaxel by the use of hyaluronan |
| US6087350A (en) | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
| GB9727524D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Synergistic antitumor composition containing a biologically active ureido compound |
| US20020015724A1 (en) | 1998-08-10 | 2002-02-07 | Chunlin Yang | Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing |
| EP1117835A4 (en) | 1998-10-02 | 2005-03-09 | Genzyme Corp | PREVENTION OF ADHERENCES |
| IT1303735B1 (it) | 1998-11-11 | 2001-02-23 | Falorni Italia Farmaceutici S | Acidi ialuronici reticolati e loro usi medici. |
| HK1041209A1 (zh) * | 1999-01-13 | 2002-07-05 | Meditech Research Limited | 加強藥物療效的成份及方法 |
| EP1044977B1 (en) | 1999-03-09 | 2002-05-02 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Camptothecin derivatives having antitumor activity |
| IT1306643B1 (it) | 1999-04-08 | 2001-10-02 | Fidia Advanced Biopolymers Srl | Processo per la preparazione dei composti autoreticolati dell'acidoialuronico e dei suoi derivati ottenibili mediante la tecnica |
| SE9904121D0 (sv) | 1999-11-15 | 1999-11-15 | Gustaf Jederstroem | Hydrophobe biomolecular structure |
| CA2395493C (en) | 1999-12-28 | 2010-06-22 | Bioniche Life Sciences Inc. | Hyaluronic acid in the treatment of cancer |
| US6749865B2 (en) | 2000-02-15 | 2004-06-15 | Genzyme Corporation | Modification of biopolymers for improved drug delivery |
| AUPQ879500A0 (en) | 2000-07-14 | 2000-08-10 | Meditech Research Limited | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease |
| US9066919B2 (en) | 2000-07-14 | 2015-06-30 | Alchemia Oncology Pty Limited | Hyaluronan as a chemo-sensitizer in the treatment of cancer |
| ATE312076T1 (de) | 2001-02-22 | 2005-12-15 | Anika Therapeutics Inc | Thiol-modifizierte hyaluronan-derivate |
| CA2458856C (en) | 2001-08-27 | 2011-02-15 | Meditech Research Limited | Improved therapeutic protocols |
| EP1480656A4 (en) | 2002-02-15 | 2007-07-18 | Res Dev Foundation | ADENOVIRAL TRANDUCTION INDUCED BY HYALURONIC ACID |
| JP2004262777A (ja) | 2003-02-27 | 2004-09-24 | Shiseido Co Ltd | アセチル化ヒアルロン酸含有眼用医薬組成物 |
| WO2006047744A2 (en) | 2004-10-26 | 2006-05-04 | Agennix Incorporated | Compositions of lactoferrin related peptides and uses thereof |
| CA2616607C (en) | 2005-07-27 | 2015-06-02 | Alchemia Oncology Pty Limited | Therapeutic protocols using hyaluronan |
| EA013877B1 (ru) | 2005-09-07 | 2010-08-30 | Алкемиа Онколоджи Пти Лимитед | Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения |
-
2000
- 2000-07-14 AU AUPQ8795A patent/AUPQ879500A0/en not_active Abandoned
-
2001
- 2001-07-13 CA CA2382560A patent/CA2382560C/en not_active Expired - Fee Related
- 2001-07-13 WO PCT/AU2001/000849 patent/WO2002005852A1/en not_active Ceased
- 2001-07-13 GB GB0204331A patent/GB2368525B/en not_active Expired - Fee Related
- 2001-07-13 US US10/088,774 patent/US20030180382A1/en not_active Abandoned
- 2001-07-13 CN CN01802357A patent/CN1388760A/zh active Pending
- 2001-07-13 NZ NZ517359A patent/NZ517359A/en not_active IP Right Cessation
- 2001-07-13 JP JP2002511783A patent/JP5548328B2/ja not_active Expired - Fee Related
- 2001-07-13 EP EP01951219A patent/EP1301209A4/en not_active Ceased
-
2002
- 2002-02-25 ZA ZA200201561A patent/ZA200201561B/en unknown
-
2005
- 2005-07-27 US US11/191,407 patent/US8287894B2/en not_active Expired - Fee Related
-
2006
- 2006-05-01 US US11/415,612 patent/US8388993B2/en not_active Expired - Fee Related
-
2012
- 2012-05-30 JP JP2012123354A patent/JP2012162569A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004502789A5 (enExample) | ||
| Si et al. | Advances in delivery of Irinotecan (CPT-11) active metabolite 7-ethyl-10-hydroxycamptothecin | |
| AU758191B2 (en) | Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate | |
| WO2005117954A3 (en) | Compositions and methods for treatment of neovascular diseases | |
| JP2012502904A5 (enExample) | ||
| WO2005072061A3 (en) | Conjugates for cancer therapy and diagnosis | |
| JP6223995B2 (ja) | カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途 | |
| Mollica et al. | Delivery methods of camptothecin and its hydrosoluble analogue irinotecan for treatment of colorectal cancer | |
| CA2382560A1 (en) | Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease | |
| WO2005025501A3 (en) | Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer | |
| JP2008540364A5 (enExample) | ||
| De Jonge et al. | The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies | |
| Legarza et al. | Novel camptothecin derivatives | |
| JP2003509372A (ja) | リン酸エストラムスチンおよびアミノ酸の非経口使用のための処方 | |
| JP2006504721A5 (enExample) | ||
| CA2562756A1 (en) | Methods for controlling angiogenesis and cell proliferation using a desulphatohirudin | |
| Raymond et al. | Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma | |
| TWI454280B (zh) | Pharmaceutical composition or combination | |
| US20200237747A1 (en) | Combination-based treatment method | |
| Pizzolato et al. | Irinotecan (Campto®) in the treatment of pancreatic cancer | |
| WO2004090537A3 (en) | Methods to individualize combination therapy | |
| Beslija | The role of anthracyclines/anthraquinones in metastatic breast cancer | |
| AU2009240908B2 (en) | Methods of administering antitumor agent comprising deoxycytidine derivative | |
| Hochberg et al. | Lack of efficacy of 9-aminocamptothecin in adults with newly diagnosed glioblastoma multiforme and recurrent high-grade astrocytoma | |
| JP2009046450A (ja) | 抗がん剤へのヒアルロン酸添加 |